stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Operating cash flow
Indivior Pharmaceuticals Inc.'s operating cash flow for fiscal 2025 was −$27.0M, compared with $36.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $96.0M. Over the past ten years it has ranged from −$300.0M (fiscal 2023) to $407.0M (fiscal 2016); the current reading is higher than 27% of that period. Indivior Pharmaceuticals Inc. ranks 26th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$27.0M | — |
| FY2024 | $36.0M | — |
| FY2023 | −$300.0M | — |
| FY2022 | −$4.0M | — |
| FY2021 | $353.0M | — |
| FY2020 | −$193.0M | — |
| FY2019 | $151.0M | (50.17%) |
| FY2018 | $303.0M | 2.71% |
| FY2017 | $295.0M | (27.52%) |
| FY2016 | $407.0M | 27.19% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $97.0M | (57.64%) |
| Jun 2026 | $229.0M | — |
| Mar 2026 | −$9.0M | — |
| Dec 2025 | −$221.0M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $198.8M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $180.6M |
| LQDA Liquidia Corporation compare | $167.7M |
| SUPN Indivior Pharmaceuticals Inc. | $96.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$126.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement